阿达木单抗对类风湿关节炎、银屑病关节炎和强直性脊柱炎患者工作效率及睡眠指标影响的真实世界证据。
Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
作者信息
Tektonidou Maria G, Katsifis Gkikas, Georgountzos Athanasios, Theodoridou Athina, Koukli Eftychia-Maria, Kandili Anna, Giokic-Kakavouli Giasna, Karatsourakis Theofilos-Diamantis
机构信息
1st Department of Propaedeutic and Internal Medicine, Joint Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, 17 Agiou Thoma Str., Athens, 11 527, Greece.
Rheumatology Clinic Naval Hospital of Athens, Athens, Greece.
出版信息
Ther Adv Musculoskelet Dis. 2020 Sep 28;12:1759720X20949088. doi: 10.1177/1759720X20949088. eCollection 2020.
OBJECTIVE
Our aim was to evaluate the effect of adalimumab on work productivity measures, overall activity impairment, and sleep quality in patients with active moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) treated in routine care settings in Greece and determine factors associated with work impairment and sleep disturbance.
METHODS
Patients with active moderate to severe RA ( = 184), PsA ( = 166), and AS ( = 150) were enrolled in this 24-month, prospective, observational study at 80 hospital outpatient clinics and private practices throughout Greece. Patients received adalimumab alone or in combination with standard antirheumatic therapies according to routine care. Work productivity and sleep were assessed through two patient-reported outcome measures: the Work Productivity and Activity Impairment-General Health questionnaire and the Medical Outcomes Study Sleep Scale (MOS-SS). Pearson correlation coefficients were estimated to assess the association of work impairment and sleep disturbances with disease activity scores.
RESULTS
In the overall population, adalimumab significantly lowered absenteeism [mean (95% confidence interval) reduction, 18.9% (13.3-24.5%); = 100]; presenteeism [40.0% (33.8-46.3%); = 98], overall work productivity impairment [46.8% (40.4-53.2%); = 94], activity impairment [47.0% (44.3-49.6); = 421], and the MOS-SS sleep problems index [31.6 (29.5-34.1); = 421] after 24-month treatment ( < 0.001). Significant improvements were also noted across the RA, PsA, and AS subpopulations ( < 0.05). Improvements in overall work impairment and sleep disturbance positively correlated with improvements in disease activity measures.
CONCLUSION
Adalimumab improves work productivity and sleep problems while lowering disease activity in patients with moderate to severe RA, PsA, and AS managed in real-world settings.
目的
我们的目的是评估阿达木单抗对希腊常规护理环境中接受治疗的活动性中度至重度类风湿关节炎（RA）、银屑病关节炎（PsA）或强直性脊柱炎（AS）患者的工作效率指标、总体活动障碍和睡眠质量的影响，并确定与工作障碍和睡眠障碍相关的因素。
方法
184例活动性中度至重度RA患者、166例PsA患者和150例AS患者参与了这项在希腊80家医院门诊和私人诊所进行的为期24个月的前瞻性观察研究。患者根据常规护理单独接受阿达木单抗治疗或与标准抗风湿疗法联合使用。通过两种患者报告的结局指标评估工作效率和睡眠情况：工作效率与活动障碍-一般健康问卷和医学结局研究睡眠量表（MOS-SS）。估计Pearson相关系数以评估工作障碍和睡眠障碍与疾病活动评分之间的关联。
结果
在总体人群中，经过24个月的治疗后，阿达木单抗显著降低了旷工率[平均（95%置信区间）降低，18.9%（13.3-24.5%）；n = 100]；出勤主义[40.0%（33.8-46.3%）；n = 98]，总体工作效率障碍[46.8%（40.4-53.2%）；n = 94]，活动障碍[47.0%（44.3-49.6）；n = 421]，以及MOS-SS睡眠问题指数[31.6（29.5-34.1）；n = 421]（P < 0.001）。在RA、PsA和AS亚组中也观察到了显著改善（P < 0.05）。总体工作障碍和睡眠障碍的改善与疾病活动指标的改善呈正相关。
结论
在现实环境中管理的中度至重度RA、PsA和AS患者中，阿达木单抗在降低疾病活动度的同时改善了工作效率和睡眠问题。
Zotero 插件